Diploma (LON:DPLM) Share Price Passes Above 200 Day Moving Average - Here's What Happened

Diploma PLC (LON:DPLM - Get Free Report) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 4,252.69 ($56.60) and traded as high as GBX 4,260 ($56.69). Diploma shares last traded at GBX 4,251.86 ($56.59), with a volume of 364,165 shares trading hands.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. upped their price target on Diploma from GBX 4,370 ($58.16) to GBX 4,420 ($58.82) and gave the company a "neutral" rating in a research report on Tuesday, January 14th.

Diploma Price Performance

The business has a 50-day simple moving average of GBX 3,926.44 and a 200 day simple moving average of GBX 4,252.69. The stock has a market cap of £5.65 billion, a P/E ratio of 48.69, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. The company has a current ratio of 2.17, a quick ratio of 0.80 and a debt-to-equity ratio of 62.17.

Insider Activity at Diploma

In other Diploma news, insider David S. Lowden bought 750 shares of the business's stock in a transaction that occurred on Friday, March 21st. The shares were bought at an average price of GBX 3,928 ($52.28) per share, for a total transaction of £29,460 ($39,206.81). Also, insider Ian El-Mokadem bought 500 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average price of GBX 3,948 ($52.54) per share, for a total transaction of £19,740 ($26,270.96). 0.52% of the stock is owned by corporate insiders.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.